Penumbra: Richly-valued but trades well after earnings
Nov 5th, 3:12 pm
PEN Q3 top line beat of 111.8M vs consensus 102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M
Nov 6th, 9:15 am
PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for 
JNJ 
MDT or even 
EW
Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN
PEN Q3 top line beat of 111.8M vs consensus 102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38MNov 6th, 9:15 am
PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for JNJ MDT or even EWWells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.